Is Ipilimumab on the market?

Ipilimumab (Ipilimumab) was launched abroad in 2011. It is an immunotherapy drug developed and approved by the American pharmaceutical company Bristol-Myers Squibb. The launch of ipilimumab marks an important development in the field of immunotherapy, as it provides a new way to deal with some malignancies, especially malignant melanoma (melanoma),It is the first CTLA-4 (cytotoxic T lymphocyte antigen 4) inhibitor approved by the U.S. Food and Drug Administration (FDA). IpilimumabThe original drug has been launched domesticallyand is sold under the trade name Yiwo. Due to its short time on the market, its purchasing channels are not yet clear.